Sign up
Pharma Capital

Regeneus welcomes positive step forward for Progenza’s US patent

Progenza is the company’s lead cell therapy technology platform.
filing cabinet with file marked 'patents'
Progenza is being developed to treat osteoarthritis and other musculoskeletal diseases

Regeneus Ltd (ASX:RGS) welcomes the United States Patent Office’s notice of allowance for issuance of a patent covering the composition and use of Progenza.

Progenza is an allogeneic off-the-shelf stem cell technology platform developed for the treatment of knee osteoarthritis and other inflammatory conditions.

READ: Regeneus director supports stem cell technology through on-market purchase

Issuance of the patent for United States Patent Application No. 14/342479 entitled ‘Therapeutics using adipose cells and cell secretions’ will provide commercial rights in the United States through to 2032.

Corresponding patents have been granted in Australia and Japan and are being pursued for grant in other key territories including Europe.

View full RGS profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.